Ellen Fung

Dr. Ellen Fung


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2006 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EFEllen Fung
Ellen Fung
PHPaul R. Harmatz
Paul R. Harmatz
PLPhillip D.K. Lee
Phillip D.K. Lee
MMMeredith Milet
Meredith Milet
RBRita Bellevue
Rita Bellevue
TGthe Multi‐Centre Study of Iron Overload Research Group.
the Multi‐Centre Study of Iron Overload Research Group.

14 March 2007 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
EFEllen Fung
Ellen Fung
PHPaul Harmatz
Paul Harmatz
MMMeredith Milet
Meredith Milet
SBSamir K. Ballas
Samir K. Ballas
LCLaura De Castro
Laura De Castro
TGThe Multi‐Center Study of Iron Overload Research Group
The Multi‐Center Study of Iron Overload Research Group
A natural history study was conducted in 142 Thalassemic (Thal), 199 transfused Sickle Cell Disease (Tx‐SCD, n = 199), and 64 non‐Tx‐SCD subjects to describe the frequency of iron‐related morbidity and mortality. Subjects recruited from 31 centers in the US, Canada or the UK were similar with respect to age (overall: 25 ± 11 years, mean ± SD) and gender (52% female). We found that Tx‐SCD subjects were hospitalized more frequently compared with Thal or non‐Tx‐SCD (P < 0.001). Among those hospitalized, Tx‐SCD adult subjects were more likely to be unemployed compared with Thal (RR = 1.6, 95% CI 1.0–2.5) or non‐Tx‐SCD (RR = 3.1, 95% CI 1.3–7.3). There was a positive relationship between the severity of iron overload, assessed by serum ferritin, and the frequency of hospitalizations (r= 0.20; P = 0.009). Twenty‐three deaths were reported (6 Thal, 17 Tx‐SCD) in 23.5 ± 10 months of follow‐up. Within the Tx‐SCD group, those who died began transfusion (25.3 vs. 12.4 years, P < 0.001) and chelation therapy later (26.8 vs. 14.2 years, P = 0.01) compared with those who survived. The unadjusted death rate in Thal was lower (2.2/100 person years) compared with that in Tx‐SCD (7.0/100 person years; RR = 0.38: 95% CI 0.12–0.99). However, no difference was observed when age at death was considered. Despite improvements in therapy, death rate in this contemporary sample of transfused adult subjects with Thal or SCD is 3 times greater than the general US population. Long term follow‐up of this unique cohort of subjects will be helpful in further defining the relationship of chronic, heavy iron overload to morbidity and mortality. Am. J. Hematol., 2007.

1 July 2008 in Bone
Verified
Journal Article
Closed access
EFEllen Fung
Ellen Fung
PHPaul R. Harmatz
Paul R. Harmatz
MMMeredith Milet
Meredith Milet
TCThomas Coates
Thomas Coates
ATAlexis A. Thompson
Alexis A. Thompson
EVElliott P. Vichinsky
Elliott P. Vichinsky

1 October 2013 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
EFEllen Fung
Ellen Fung
JKJanet L Kwiatkowski
Janet L Kwiatkowski
JHJames N Huang
James N Huang
GGGinny Gildengorin
Ginny Gildengorin
JKJanet C King
Janet C King
EVElliott P Vichinsky
Elliott P Vichinsky
Background: Patients with thalassemia major (Thal) frequently have low plasma zinc, which has been associated with low bone mass.Objective: The objec

2 August 2010 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EFEllen Fung
Ellen Fung

1 July 2012 in Journal of the Academy of Nutrition and Dietetics
Verified
Journal Article
Closed access
EFEllen Fung
Ellen Fung
YXYan Xu
Yan Xu
FTFelicia Trachtenberg
Felicia Trachtenberg
IOIsaac Odame
Isaac Odame
JKJanet L. Kwiatkowski
Janet L. Kwiatkowski
EVElliott P. Vichinsky
Elliott P. Vichinsky